{"doc_type":"other","party_a_name":"PACIRA PHARMACEUTICALS, INC.","party_b_name":"EKR THERAPEUTICS, INC.","effective_date":"2007-08-10","term_length":null,"governing_law":"New York","termination_notice_days":null,"liability_cap":"PPI liability limited to [**] US Dollars ($[**]) (Section 10.8); EKR liability limited to [**] US Dollars ($[**]) (Section 10.9), with stated exceptions (e.g., death/personal injury; certain payment obligations; certain third-party judgments).","non_solicit_clause_present":false,"data_transfer_outside_uk_eu":"unknown","risk_level":"high","risk_explanation":"This is a complex strategic licensing/distribution agreement (not a standard SaaS contract) with extensive regulatory, manufacturing, and indemnity obligations that would be high-burden for a small vendor. Key commercial terms and liability caps are heavily redacted, making risk difficult to quantify. The term can extend for 15 years from first commercial launch or until patent expiry, with renewals, creating long-tail obligations."}